First RSV Vaccine On The Horizon—Pfizer Touts Strong Trial Results As Children’s Hospitals Count Soaring Cases

日本 ニュース ニュース

First RSV Vaccine On The Horizon—Pfizer Touts Strong Trial Results As Children’s Hospitals Count Soaring Cases
日本 最新ニュース,日本 見出し
  • 📰 Forbes
  • ⏱ Reading Time:
  • 11 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 53%

Pfizer said it would ask regulators to greenlight a vaccine designed to protect infants against respiratory syncytial virus, or RSV, following strong results in late-stage clinical trials.

Pharma giant Pfizer on Tuesday said it would ask regulators to greenlight a vaccine designed to protect infants against respiratory syncytial virus, or RSV, following strong results in late-stage clinical trials, a potential gamechanger in efforts to combat the common but potentially lethal infection as cases soar and children’s hospitals struggle to cope....

The shot was nearly 82% effective at preventing a severe form of lower respiratory tract illness from RSV during the baby’s first 90 days of life, Pfizer said, and about 70% effective over the first six months.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

Forbes /  🏆 394. in US

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data showsPfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data showsPfizer said it will submit an application to the Food and Drug Administration for the RSV vaccine's approval by the end of 2022.
続きを読む »

RSV Vaccine Protected Infants From Severe Cases, Pfizer Study FindsRSV Vaccine Protected Infants From Severe Cases, Pfizer Study FindsAn RSV vaccine given to pregnant women significantly reduced the risk of severe cases in their infants. The study comes as doctors report unusually high numbers of the respiratory illness.
続きを読む »

Pfizer announces promising developments for 1st maternal RSV vaccinePfizer announces promising developments for 1st maternal RSV vaccineAfter decades of researching respiratory syncytial virus, an illness especially dangerous for newborns and the elderly, scientists this week announced a major development in plans for a possible vaccine that could be available as soon as next year.
続きを読む »

Pfizer to seek regulatory approval as strong RSV vaccine data lifts hopesPfizer to seek regulatory approval as strong RSV vaccine data lifts hopesThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
続きを読む »

RSV Vaccine Given During Pregnancy Protects Newborns: PfizerRSV Vaccine Given During Pregnancy Protects Newborns: PfizerNew trial data from drugmaker Pfizer shows promising effectiveness of a vaccine given to mothers during pregnancy that later protects infants in their first months from the most devastating effects of respiratory syncytial virus, or RSV.
続きを読む »

Pfizer Says Its Maternal RSV Vaccine Can Protect Newborns From Severe IllnessPfizer Says Its Maternal RSV Vaccine Can Protect Newborns From Severe IllnessPfizer announced Tuesday that a large international study found vaccinating moms-to-be was nearly 82% effective at preventing severe cases of RSV in their babies’ most vulnerable first 90 days of life.
続きを読む »



Render Time: 2025-03-05 02:30:00